4//SEC Filing
Edge Therapeutics, Inc. 4
Accession 0001140361-15-037183
$PDSBCIK 0001472091operating
Filed
Oct 7, 8:00 PM ET
Accepted
Oct 8, 4:13 PM ET
Size
27.5 KB
Accession
0001140361-15-037183
Insider Transaction Report
Form 4
Einhorn Andrew J.
Chief Financial Officer
Transactions
- Conversion
Common Stock
2015-10-06+24,089→ 39,279 total - Other
Common Stock
2015-10-06$7.75/sh+1,651$12,795→ 83,592 total(indirect: By LLC) - Conversion
Series C-1 Convertible Preferred Stock
2015-10-06−21,506→ 0 total(indirect: By LLC)→ Common Stock (15,720 underlying) - Conversion
Series C-2 Convertible Preferred Stock
2015-10-06−29,032→ 0 total(indirect: By LLC)→ Common Stock (21,221 underlying) - Other
Common Stock
2015-10-06$6.79/sh+2,377$16,140→ 41,656 total - Conversion
Common Stock
2015-10-06+21,221→ 36,941 total(indirect: By LLC) - Purchase
Common Stock
2015-10-06$11.00/sh+45,000$495,000→ 81,941 total(indirect: By LLC) - Conversion
Common Stock
2015-10-06+10,443→ 10,443 total - Conversion
Common Stock
2015-10-06+15,720→ 15,720 total(indirect: By LLC) - Conversion
Series B-1 Convertible Preferred Stock
2015-10-06−14,286→ 0 total→ Common Stock (10,443 underlying) - Conversion
Common Stock
2015-10-06+4,747→ 15,190 total - Conversion
Series C Convertible Preferred Stock
2015-10-06−6,494→ 0 total→ Common Stock (4,747 underlying) - Conversion
Series C-1 Convertible Preferred Stock
2015-10-06−32,956→ 0 total→ Common Stock (24,089 underlying)
Footnotes (4)
- [F1]The convertible preferred stock converted into the Issuer's common stock at a conversion ratio, as adjusted to give effect to the Issuer's 1-for-1.3681 reverse stock split effected on September 21, 2015, of one share of common stock for every 1.3681 shares of preferred stock immediately prior to the closing of the Issuer's initial public offering of common stock, and had no expiration date.
- [F2]The Reporting Person is the sole managing member of Harpua, LLC and may be deemed to beneficially own these shares. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
- [F3]The Reporting Person received a total of 2,377 shares of the Issuer's common stock which represented a payment-in-kind dividend on 39,450 shares of the Issuer's convertible preferred stock owned at the time of the dividend payment date.
- [F4]Harpua, LLC received a total of 1,651 shares of the Issuer's common stock which represented a payment-in-kind dividend on 50,538 shares of the Issuer's convertible preferred stock owned at the time of the dividend payment date. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
Documents
Issuer
Edge Therapeutics, Inc.
CIK 0001472091
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001472091
Filing Metadata
- Form type
- 4
- Filed
- Oct 7, 8:00 PM ET
- Accepted
- Oct 8, 4:13 PM ET
- Size
- 27.5 KB